Novartis announces results of Ph III trials of Beovu® (brolucizumab) versus aflibercept

Aug 17, 2021

Novartis announced the results of its Ph III trials of Beovu® (brolucizumab) versus aflibercept in patients with diabetic macular edema, reporting that Beovu® demonstrated superiority versus aflibercept in key endpoints.

Print Page Mail Article